SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today ...

Insulet Corporation PODD recently signed a global commercialization deal with Dexcom DXCM to offer an enhanced system of automated insulin delivery. As a result of this partnership, current and future ...

Insulet Corporation PODD has been progressing well with its strategies of expanding Omnipod’s market access and developing the Omnipod Horizon system. The company already seems to be on track to ...

The rate of innovation in devices for type 1 diabetes patients has accelerated rapidly in recent years, with digital technology and medical devices converging to offer new control. Most recently, ...

Insulet said it plans to pause a pivotal clinical study of its upcoming wearable insulin pump due to an anomaly in the device’s software. The company said the computer bug could cause the automated ...

Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...

Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

Omnipod ® 5 Automated Glucose Control System, Powered by Horizon™ (Omnipod 5), formerly known as the Omnipod Horizon System, is the first tubeless smartphone-controlled automated insulin delivery ...